Early results from a Phase 2 clinical trial testing lixisenatide, a medication used to treat diabetes, in people with Parkinson’s disease, indicate the treatment may slow the progression of motor symptoms. The LixiPark (NCT03439943) trial is evaluating lixisenatide’s effectiveness as add-on therapy in 156 people with early…
Gain Therapeutics’ GT-02287, an oral investigational therapy for Parkinson’s disease, was found to reduce blood levels of neurofilament light chain (NfL), a biomarker of nerve cell degeneration, in mouse models of the disorder. Further, the treatment lessened recognizable features associated with Parkinson’s symptoms — such as alpha-synuclein…
People with Parkinson’s disease can learn how to re-train their gait and improve their walking ability with the help of a new app that’s available for free on both the iOS and Android stores. Walking Tall lets users define their own training time and rhythm, and delivers a rhythmic…
RaceTrac is set to revive its “Run for Research” 5K race, scheduled for Sept. 16 at Truist Park in Atlanta, to support research for Parkinson’s disease. All proceeds, including the registration fees, will be donated to the Michael J. Fox Foundation (MJFF) research programs that seek to…
The Parkinson’s Foundation is investing $2.8 million in 30 research grants to help advance potential new therapies for Parkinson’s disease. The focus is to accelerate pioneering research into several aspects of the disease, conducted by early career researchers or those more established. The ultimate goal is to find…
Gcanrx soon will open a Phase 2 clinical trial of a neuroprotective cannabinoid treatment that the company expects could benefit people with a range of neurological conditions, including Parkinson’s disease. The safety and efficacy trial, approved to take place in Israel, is expected to begin enrolling children with…
The early appearance of minor hallucinations in people with Parkinson’s disease might be a predictor of faster cognitive decline, a recent study suggests. Among those with hallucinations, cognitive decline was also associated with electrical activity in the frontal lobe, a part of the brain that controls cognition. The study,…
Treatment with bemdaneprocel (BRT-DA01), BlueRock Therapeutics’s investigational cell-based therapy, was safe and well tolerated among patients with advanced-stage Parkinson’s disease, according to top-line results from a Phase 1 clinical trial. Furthermore, data also showed that transplantation was feasible, and there was evidence of cell survival and engraftment in…
The Parkinson’s Foundation has expanded its Global Care Network by adding four Centers of Excellence and four Comprehensive Care Centers to increase access to specialized multidisciplinary care for people with Parkinson’s disease. This expansion recognizes centers within a broad geographic region, including the first-ever designations in Wisconsin,…
Freeline Therapeutics announced plans to leverage knowledge gained from its FLT201 gene therapy program in Gaucher disease to advance a similar candidate to treat people whose Parkinson’s is tied to mutations in the GBA1 gene. “Our GBA1-linked Parkinson’s disease program is a natural extension of our…
Get regular updates to your inbox.